Back to search

University of Edinburgh

Improving outcomes for patients with Type 2 myocardial infarction

Abstract

dc:description.abstract

BACKGROUND AND AIMS: More than 100,000 patients are admitted to hospital each year with a myocardial infarction (MI) in the United Kingdom alone. Despite major advances in care, this condition remains one of the main causes of premature death worldwide. The Fourth Universal Definition states a type 1 MI occurs due to atherosclerotic plaque rupture and thrombosis. This condition is well understood, with many randomised control trials to inform clinical care which have translated to improvements in morbidity and mortality. Type 2 MI accounts for around one in four MI events and is poorly understood. It occurs due to an imbalance in myocardial oxygen supply, or unmet increase in myocardial oxygen demand, usually during another acute illness. Outcomes are poor, with just one in three patients alive at five years. Despite this, there are no clinical guidelines to aid clinicians in the assessment and treatment of this condition. The aims of this thesis are to: 1) Understand how the diagnosis of type 2 MI is applied in practice; 2) Develop novel approaches to risk stratify patients with type 2 MI for further investigation and treatment; 3) Obtain consensus on how patients with type 2 MI should be investigated and managed and ;4) Deliver a feasibility randomised controlled trial to determine the feasibility of recruitment and randomisation of patients with type 2 MI to a complex intervention. METHODS: Study one was conducted in two prospective cohort studies enrolling 48,282 and 28,783 consecutive patients with possible MI in Scotland and Sweden, respectively. We assessed the accuracy of clinical diagnoses of MI recorded in hospital records for an adjudicated diagnosis of type 1 or type 2 MI. We determined the risk of subsequent MI or cardiovascular death at one-year in those with and without a clinical diagnosis of MI. In study two, we developed a risk stratification tool (The T2-risk score) using Cox proportional hazard models constructed for MI or death at one year. Discrimination was assessed by area under the receiving operating curve (AUC). Calibration was investigated graphically. The tool was derived in consecutive patients recruited in Scotland and validated in two independent cohort studies (Sweden and Switzerland). In study three, following a systematic review, we contacted the chief investigators of all studies in type 2 MI to participate in an e-Delphi study. Open questions designed by a steering group were circulated asking participants to explain their approach to diagnosis and treatment of type 2 MI. Consensus was defined a priori as ≥70% agreement on a 5-point Likert scale. Study four was a prospective, multi-centre, parallel group with blinded endpoint evaluation (PROBE) trial in patients with type 2 MI. This trial randomised patients to a complex intervention using CT coronary angiography or echocardiography to identify coronary artery disease or left ventricular impairment versus standard care. Adherence was calculated as the number of recommendations and treatments administered at 90 days. Clinical endpoints including recurrent MI, death and heart failure hospitalisation were captured using routine data infrastructure. RESULTS: A clinical diagnosis of MI was recorded in 79% (2,506/3,187) and 17% (122/716) of patients with an adjudicated diagnosis of type 1 and type 2 MI, respectively. Patients with an adjudicated diagnosis of type 2 MI who did not have a clinical diagnosis of MI had a lower cumulative incidence of subsequent MI or cardiovascular death at one-year compared with patients with a clinical diagnosis (Scotland: 24% versus 32%; P<.001; Sweden: 21% versus 42%; P<.001). We derived the T2-risk stratification tool in 1,121 patients with type 2 MI and validated it in 250 and 253 patients from single-centre and multi-centre validation cohorts with subsequent MI or death at one year occurring in 27% (297/1,121), 26% (66/250) and 14% (35/253) of patients, respectively. The risk tool had good discrimination (area under the curve [AUC] 0.76, 95% confidence interval [CI] 0.73-0.79) and calibration, outperforming the Global Registry of Acute Coronary Events (GRACE) score. In our eDelphi study, the overall response rate from experts was 61% (42/68). There was consensus that randomised trials evaluating investigation and treatment for coronary artery disease are needed to improve outcomes (97% agreement). Experts agreed that either CT coronary angiography or a functional test should be considered (95% agreement). There was support for the use of aspirin and statin therapy in those with evidence of coronary artery disease (95% agreement), for the use of preventative therapies including ACE inhibitors, angiotensin receptor blockers and beta-blockers (92% agreement) and for revascularisation in those with obstructive coronary artery disease (81% agreement). The TARGET-Type 2 feasibility trial was delivered in an 18-month period. During the 12-month recruitment period, 403 patients with type 2 MI were identified across two participating sites. 143 patients (35%) were eligible, of whom 119 patients (83%) were approached and 60 patients (42%, age 70 [10] years, 38% women) consented and randomised to either the intervention (n=28) or standard care (n=32). The adjudicated diagnosis was type 2 MI in all participants. Adherence to recommendations was 90.7% (95%CI 85.3%-96.1%) and follow up was completed for all participants. The recruitment rate of 5 patients per month across two sites met our pre-specified target (4.7 per month). CONCLUSION: I have demonstrated that the Universal Definition of MI is not consistently applied in clinical practice where only a minority of patients with type 2 MI are identified. I have developed a risk stratification tool which can provide clinicians with guidance as to which patients with type 2 MI are more likely to benefit from further investigation and treatment. I then established expert consensus for the most appropriate further investigation and treatment strategies for patients with type 2 MI during an eDelphi process. Finally, I applied these recommendations in a multi-centre feasibility randomised controlled trial, and demonstrated it is feasible to identify, recruit and randomise patients with type 2 MI. This thesis represents the first step in improving the care of patients with type 2 MI and will inform a future multi-centre randomised controlled trial powered to evaluate the impact of investigation and treatment on clinical outcomes.

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Taggart, Cáelán Paul
Advisors dc:contributor.advisor
  • Mills, Nicholas
  • Chapman, Andrew

Subjects

dc:subject × 1

Rights

Language dc:language.iso
en

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
University of Edinburgh
Base URL
era.ed.ac.uk/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Taggart, Cáelán Paul. Improving outcomes for patients with Type 2 myocardial infarction. 2026. https://hdl.handle.net/1842/45446